IN THE CLAIMS:

Please cancel claims 13 and 16.

Please amend the claims as follows:

- 12. [amended] A method for identifying a composition which affects a [c-jun N-terminal] kinase characterized as having a molecular weight of 46 kD as determined by reducing SDS-PAGE; having serine and threonine kinase activity; and phosphorylating the c-Jun N-terminal activation domain, [which] compris[es]ing:
- a[.]) incubating components comprising the composition and the kinase or polynucleotide encoding the kinase, wherein the incubating is carried out under conditions sufficient to allow the components to interact; and
- b[.]) measuring the effect of the composition on the kinase or polynucleotide encoding the kinase.

IN THE SPECIFICATION:

Please delete the originally filed Sequence listing found at pages 63-73, and substitute the accompanying sequence listing beginning as page 63 and subsequently number the pages accordingly.

On page 2, line 22, after "phorbol ester," and before "TPA", please insert --12-O-tetradecanoylphorbol-13-acetate,--.

REMARKS

These remarks are in response to the Office Action mailed October 20, 1995. Claims 13 and 16 have been canceled without prejudice and Applicant retains the right to pursue the subject matter of these claims in a later filed continuation or divisional application. Claim 12 has been amended to incorporate the subject matter of claim 1, which is a non-elected claim. No new matter has been added. Claims 12, 14, 15 and 17 are pending.

A new sequence listing has been prepared and is submitted with this amendment, in order to amend SEQ ID NO:9. SEQ ID NO:9 is identical to originally filed FIGURE 10. Applicant